Free Trial

Pfizer (PFE) Stock Price, News & Analysis

Pfizer logo
$26.10 +0.09 (+0.33%)
Closing price 03:59 PM Eastern
Extended Trading
$26.06 -0.03 (-0.12%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pfizer Stock (NYSE:PFE)

Key Stats

Today's Range
$25.96
$26.20
50-Day Range
$24.80
$27.12
52-Week Range
$24.48
$31.54
Volume
31.27 million shs
Average Volume
34.86 million shs
Market Capitalization
$147.89 billion
P/E Ratio
35.27
Dividend Yield
6.44%
Price Target
$32.00
Consensus Rating
Moderate Buy

Company Overview

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

Pfizer Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
100th Percentile Overall Score

PFE MarketRank™: 

Pfizer scored higher than 100% of companies evaluated by MarketBeat, and ranked 5th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pfizer has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 8 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Pfizer has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pfizer's stock forecast and price target.
  • Earnings Growth

    Earnings for Pfizer are expected to decrease by -2.04% in the coming year, from $2.94 to $2.88 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pfizer is 35.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.10.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pfizer is 35.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.94.

  • Price to Earnings Growth Ratio

    Pfizer has a PEG Ratio of 0.64. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Pfizer has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pfizer's valuation and earnings.
  • Percentage of Shares Shorted

    1.34% of the outstanding shares of Pfizer have been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently decreased by 11.32%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    Pfizer is a leading dividend payer. It pays a dividend yield of 6.46%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Pfizer has been increasing its dividend for 16 years.

  • Dividend Coverage

    The dividend payout ratio of Pfizer is 227.03%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Pfizer will have a dividend payout ratio of 58.33% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

  • Read more about Pfizer's dividend.
  • Percentage of Shares Shorted

    1.34% of the outstanding shares of Pfizer have been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently decreased by 11.32%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Pfizer has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 98 news articles for Pfizer this week, compared to 41 articles on an average week.
  • Search Interest

    309 people have searched for PFE on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.
  • MarketBeat Follows

    116 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 9% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pfizer insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,240.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.06% of the stock of Pfizer is held by insiders.

  • Percentage Held by Institutions

    68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pfizer's insider trading history.
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

Toronto, Ontario, Canada - February 14, 2021 : A health worker table with shots of the American USA Moderna vaccine. Name on the screen, vials and syringes containing messenger mRNA technology vaccine
After a Reset Year, Is Moderna Stock Poised for a Comeback? (PFE)
Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?
Poker chips and dollar Money bills on green cloth. High quality photo - stock image
Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns (PFE)
Explore established industry leaders with impressive dividend yields that are demonstrating the potential for growth and continued performance in 2025.
Breaking our next big financial story
Every few years a financial story captures the attention of investors... These are stories that often impact everyone and see huge amounts of money change hands - like the collapse of the banks, the emergence of cryptocurrencies, or the sudden rise of artificial intelligence.
Stuttgart, Germany - 07-21-2024: Person holding cellphone with webpage of Canadian uranium mining company Cameco Corporation in front of logo. Focus on center of phone display. — Stock Editorial Photography
Top 3 Stocks Seeing a Spike in Call Option Volume (PFE)
Three stocks reported unusual call option volume this month, and the reasons why would make sense to all investors and Wall Street analysts.
Pfizer stock
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca
Jefferies Keeps Their Buy Rating on Pfizer (PFE)
Why Is Prem Watsa Bullish On Pfizer Inc. (PFE) Now?
See More Headlines

PFE Stock Analysis - Frequently Asked Questions

Pfizer's stock was trading at $26.53 at the beginning of the year. Since then, PFE shares have decreased by 2.0% and is now trading at $26.0050.
View the best growth stocks for 2025 here
.

Pfizer Inc. (NYSE:PFE) released its quarterly earnings data on Tuesday, October, 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The company's revenue for the quarter was up 31.2% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Pfizer: ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and others.

Top institutional investors of Pfizer include Robeco Institutional Asset Management B.V. (0.11%), Swedbank AB (0.09%), Nordea Investment Management AB (0.07%) and KBC Group NV (0.06%). Insiders that own company stock include Pfizer Inc, William R Carapezzi Jr, Jennifer B Damico and Scott Gottlieb.
View institutional ownership trends
.

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include Scilex (SCLX), Salesforce (CRM), Chevron (CVX), AbbVie (ABBV), Johnson & Johnson (JNJ), Meta Platforms (META) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
10/29/2024
Ex-Dividend for 12/2 Dividend
11/08/2024
Dividend Payable
12/02/2024
Today
1/24/2025
Ex-Dividend for 3/7 Dividend
1/24/2025
Next Earnings (Estimated)
2/04/2025
Dividend Payable
3/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71708110
Employees
88,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$45.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+22.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
16 Analysts

Profitability

Net Income
$2.12 billion
Pretax Margin
6.49%

Debt

Sales & Book Value

Annual Sales
$58.50 billion
Cash Flow
$2.98 per share
Book Value
$15.81 per share

Miscellaneous

Outstanding Shares
5,666,990,000
Free Float
5,663,590,000
Market Cap
$147.77 billion
Optionable
Optionable
Beta
0.64

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSE:PFE) was last updated on 1/24/2025 by MarketBeat.com Staff
From Our Partners